Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4563 Clinical case of a young woman with acromegaly, hyperprolactinemia and pituitary tumour with mixed morphology of adenoma and gangliocytoma

Introduction: Acromegaly is a rare disorder that develops due to persistent hypersecretion of somatotropic hormone in adults after closure of the growth plates. In the majority of cases, the cause is a pituitary adenoma.

Conference:

Presenting Author:

Authors: Markova M, Kirova I, Elenkova A, Robeva R, Zacharieva S,

Keywords: acromegaly, hyperprolactinemia, pituitary adenoma, gangliocytoma,

#4471 Acromegaly and small intestinal neuroendocrine tumours: Association or coincidence?

Introduction: Neuroendocrine tumours of the small intestine (SI-NETs), although rare, are the most prevalent primary neoplasms of this organ. Acromegaly is characterised by excessive secretion of growth hormone (GH), typically due to a pituitary adenoma, but in rare cases, it can result from ectopic secretion of GH-releasing hormone (GHRH) by non-pituitary tumours, particularly NETs of the lung or pancreas.

Conference:

Presenting Author: G. Martins R

Authors: Martins Fernandes A, Silva L, Serranito M, Elvas A, Santos J,

Keywords: neuroendocrine tumour, small intestinal neuroendocrine tumour, acromegaly,

#4074 Clinical, genetic and histopathological characterisation of patients with multiple endocrine neoplasia type 1 in two high complexity hospitals in Medellín, Colombia

Introduction: Limited observational data exist regarding the characterization of patients with Multiple Endocrine Neoplasia Type 1 (MEN-1) in Latin America, particularly in Colombia. This scarcity has led to a reliance on studies that may not precisely depict the actual behaviour of the disease within the population.

Conference:

Presenting Author:

Authors: Roman-Gonzalez A, Gil-Gonzalez M, Pérez-Giraldo E, Agredo Delgado V, Lopez-Montoya V,

Keywords: multiple endocrine neoplasia type 1, neuroendocrine tumor, acromegaly, cushing disease, hyperparathyroidism,

#4060 Interim safety and exploratory efficacy results of a phase 2, randomised, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome

Introduction: Carcinoid Syndrome (CS) is the most common functional NET syndrome. It is characterized by watery diarrhea or cutaneous flushing. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS. Paltusotine has been shown to maintain IGF-1 control at levels similar to injected depot SRLs.

Conference:

Presenting Author:

Authors: Usiskin K, Chauhan A, Mui C, Dillon J, Fan X,

Keywords: oral, paltusotine, carcinoid syndrome, phase II,